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Abstract
It is not possible to identify all pregnancies at risk of neonatal hypoxic-ischemic encephalopathy (HIE). Many women use
some form of analgesia during childbirth and some anesthetic agents have been shown to be neuroprotective when used
as analgesics at subanesthetic concentrations. In this study we sought to understand the effects of two anesthetic agents
with presumptive analgesic activity and known preconditioning-neuroprotective properties (sevoflurane or xenon), in
reducing hypoxia-induced brain damage in a model of intrauterine perinatal asphyxia. The analgesic and neuroprotective
effects at subanesthetic levels of sevoflurane (0.35%) or xenon (35%) were tested in a rat model of intrauterine perinatal
asphyxia. Analgesic effects were measured by assessing maternal behavior and spinal cord dorsal horn neuronal activation
using c-Fos. In separate experiments, intrauterine fetal asphyxia was induced four hours after gas exposure; on post-insult
day 3 apoptotic cell death was measured by caspase-3 immunostaining in hippocampal neurons and correlated with the
number of viable neurons on postnatal day (PND) 7. A separate cohort of pups was nurtured by a surrogate mother for 50
days when cognitive testing with Morris water maze was performed. Both anesthetic agents provided analgesia as reflected
by a reduction in the number of stretching movements and decreased c-Fos expression in the dorsal horn of the spinal cord.
Both agents also reduced the number of caspase-3 positive (apoptotic) neurons and increased cell viability in the
hippocampus at PND7. These acute histological changes were mirrored by improved cognitive function measured remotely
after birth on PND 50 compared to control group. Subanesthetic doses of sevoflurane or xenon provided both analgesia
and neuroprotection in this model of intrauterine perinatal asphyxia. These data suggest that anesthetic agents with
neuroprotective properties may be effective in preventing HIE and should be tested in clinical trials in the future.
Citation: Yang T, Zhuang L, Rei Fidalgo AM, Petrides E, Terrando N, et al. (2012) Xenon and Sevoflurane Provide Analgesia during Labor and Fetal Brain Protection
in a Perinatal Rat Model of Hypoxia-Ischemia. PLoS ONE 7(5): e37020. doi:10.1371/journal.pone.0037020
Editor: Ruth Landau, University of Washington, United States of America
Received November 29, 2011; Accepted April 12, 2012; Published May 17, 2012
Copyright:  2012 Yang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant (SP4385) from Action Medical Research, West Sussex, UK, to Dr. Ma. Drs. Yang and Zhuang were supported by the
fellowship from the Chinese Society of Anesthesiology, Beijing, China. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: d.ma@imperial.ac.uk
Introduction
Neonatal hypoxic ischemic encephalopathy (HIE) affects 1–3
per 1000 term births in the developed world [1], associating with
high mortality and lifelong chronic disabilities [2,3]. Ten to 15%
of infants with moderate to severe neonatal encephalopathy will
die; 15% of the survivors will develop cerebral palsy and a larger
proportion will present with significant disabilities including global
developmental delay, cognitive problems, deafness and epilepsy.
Although therapeutic hypothermia has been proven effective and
safe in reducing neurological deficits and mortality [4], a large
proportion (up to 50%) of treated infants will encounter adverse
outcomes. On a global scale perinatal asphyxia is an immense
problem with almost one quarter of the world’s 4 million neonatal
deaths being attributed to perinatal asphyxia [5]. Thus recogniz-
ing, treating, and preventing intra-uterine hypoxia-ischemia is one
of the main priorities of perinatal medicine.
We previously reported on the neuroprotective effects of xenon
and sevoflurane preconditioning in a model of neonatal asphyxia
[6]. The in vivo study assessed 7 day old rats but could not
effectively reproduce the intra-uterine environment in which HIE
normally occurs. In the present study we have used a validated
model of nociceptive parturition [7] and intrauterine ischemic
brain damage [8] to test the ability of xenon and sevoflurane in
providing labor analgesia and neuroprotection.
Materials and Methods
The study was approved by the Home Office (UK) and
conforms to the United Kingdom Animals (Scientific Procedures)
Act of 1986. All efforts were made to minimize animal suffering
and the number of animals used. Pregnant Sprague-Dawley (SD)
rats (300–350 g) were housed in individual cages in a 12-h-light/
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12-h-dark cycle in temperature (22–23uC) and humidity-controlled
environment with free access to standard laboratory chow.
Labor analgesia
We used a validated parturition nociceptive model [7] to
investigate the analgesic efficacy of xenon and sevoflurane. On
gestation day 21, SD rat dams received 5 mg/kg Mifepristone
(Sigma, UK) by oral gavage to induce parturition the following
day [7]. On gestation day 22, the laboring rats were placed in a
transparent anesthetic chamber with a video camera positioned
below the chamber to record the behavior of the dams from 9 am
until the first pup was delivered. Dams received 0.35% sevoflurane
or 35% xenon (Air Liquide, UK) in 30% oxygen balanced by
nitrogen. Both concentrations were obtained from our pilot
studies, in which we tested sevoflurane or xenon from high
concentrations (0.8% and 50% respectively) to lower levels
gradually. We found 0.35% sevoflurane or 35% xenon did not
affect respiratory function by counting respiratory rate but not
blood gas measurement due to technical difficulty and not prolong
the duration of labor. Animals from naı¨ve or control group
received 30% oxygen plus 70% nitrogen.
Behavioral analysis: The numbers of stretching behaviors,
either inward turning of one hind paw or straining and squashing
of the lower abdomen to the floor [7], were counted offline by an
investigator blinded to the experimental protocol for the 90 min
period preceding the expulsion of the first pup.
Immunohistochemistry: One hour after giving birth to the
first pup, the dams were deeply anesthetized with sodium
pentobarbital (100 mg/kg, i.p.) and perfused transcardially with
ice-cold heparinized 0.1 M phosphate buffer solution (PBS)
followed by 4% paraformaldehyde (PFA) in 0.1 M PBS at
pH 7.4 (VWR International, UK), the whole spinal cord was
removed. After 24 hours fixation in 4% PFA, the lumbosacral
enlargement of the spinal cord was embedded in optimal cutting
temperature compound (OCT, Sakura, UK) and sectioned
transversely at 30 mm intervals and stained for c-Fos as previously
described [9]. Briefly, sections were washed in 0.01 M PBS,
quenched for 30 min in a solution of methanol containing 3%
hydrogen peroxide, then incubated for 1 h in blocking solution
(3% normal donkey serum), followed by incubation overnight in
rabbit anti c-Fos antibody (1:500, Santa Cruz, UK). Following
incubation with primary antibody, the sections were incubated for
1 h in secondary antibody (1:200 donkey anti-rabbit, Millipore,
UK). Afterwards, ABC reagent was applied (standard Vectastain
ABC Elite Kit, Vector Labs, UK) for 2 h. Staining was revealed by
3,39-diaminobenzidine (DAB, Vector Labs, UK) for 5 min for
positive c-Fos cell quantification analysis. Counting of cells was
made by an investigator blinded to the experimental protocol by
406magnification. Four high magnifications in the dorsal horn
layer I–II at the lumbosacral of spinal cord were chosen randomly
from each slide, and three slides were evaluated of each animal.
Fetal asphyxia
Separate cohorts of dams (without mifepristone treatment)
received 0.35% sevoflurane or 35% xenon in 30% oxygen
balanced by nitrogen for 4 hours on gestation day 22 from 8am.
Animals from naı¨ve or control group received 30% oxygen plus
70% nitrogen. Dams were sacrificed by cervical dislocation and
uterine horns were removed and placed in a water-bath at 37uC
for 10 min to induce hypoxic-ischemic insult 4 hours after gas
exposure. The dams giving birth before the surgery and the pups
they delivered were discarded from the study. Fetal asphyxia was
performed as previously described [8]. Pups were rapidly delivered
from the uterus, the umbilical cord ligated, and pups were cleaned
and manually stimulated to initiate breathing in an incubator at
37uC in air, for 1 hour. Pups born after a spontaneous vaginal
delivery were used as the naı¨ve control group. After cesarean
delivery, pups were placed with a surrogate mother for subsequent
nurturing. Pups were allowed to live for 3, 7 or 50 days [8].
Immunohistochemistry and histology: On Postnatal Day
(PND) 3 and 7 [8], pups were deeply anesthetized with
pentobarbital (100 mg/kg, i.p.) and perfused with 4% PFA. Brains
were harvested and stained for caspase-3 (1:5000, Cell Signaling
Technology, UK) as previously described [8]. Paraffin sections,
5 mm in thickness, were stained with cresyl violet. Staining was
obtained by 0.5% cresyl violet solution in distilled water and the
slides were de-colored with 95% ethanol. Photomicrographs were
taken using an Olympus BX-60 microscope and captured with a
Zeiss KS-300 color 3CCD camera (three images/animals in CA1
area). The counting for caspase-3 positive cells or cresyl violet
staining healthy cells was performed by an investigator who was
blinded to the interventional group. In our previous work, we
demonstrated that after the intrauterine ischemia/hypoxia injury,
the differences of neuroapoptosis and neuron death between the
injury groups and control groups are consistent on PND 1, 3 and
7. Because of the excessive neuronal sprouting and neurogenesis
on PND 1 and 3, we use PND 7 as the time point for evaluation of
morphological change in hippocampus. However, PND 3 is
preferable for caspase 3 evaluation because this enzyme is rapidly
degraded and hard to be assessed at PND 7 [8].
Neurocognitive Testing with Morris Water Maze
(WM): Neurocognitive outcome was evaluated daily (starting on
PND 50) using Morris water maze (WM) [10] with a computerized
video tracking system (EthoVisionH; Noldus, Wageningen, The
Netherlands). Briefly, WM consisted of a circular pool 110 cm in
diameter and 60 cm in height, filled to a depth of 30 cm with
water (2460.5uC). A hidden submerged platform was placed in
one quadrant 2.5 cm below water surface. Rats were placed in the
water in a dimly lit room with visual clues around room wall. The
time of locating the submerged platform (defined as the latency-cut
off time 90 sec) was measured. The longer the time required to
locate the platform indicates the more impairment in spatial
learning and memory components of neurocognition. Four trials
tests were performed for each rat every day. Each trial started
from a different quadrant. Testing was consecutively repeated for
5 days. On testing day 6, each animal was subjected to a probe
trial (60 s cut off), where they were tested in the absence of the
platform. The time spent in the 20-cm-diameter area where the
platform was located during previous testing was recorded and
represents an index of memory.
Data analysis
The results are expressed as mean 6 SEM. Data was analyzed
with one-way analyses of variance followed by post hoc Newman-
Keuls test wherever appropriate or unpaired t-test using
SPSSv13.0 (SPSS lnc. Chicago, IL, USA). A p value,0.05 was
considered to be a statistically significant.
Results
Labor analgesia
Nociceptive behavior-labor pain: In order to assess the
effects of anesthetic exposure on pain-related behavior we
measured stretches. Following exposure to either xenon or
sevoflurane, uterine contraction-related pain (stretching behavior)
in the 90 min period prior delivery was lower in the xenon (4666)
and sevoflurane (3162) groups as compared to controls (oxygen
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enriched air exposure only) (185647) prior to delivery of the first
pup (p,0.01, n = 4) (Figure 1).
Neuronal activation during labor pain: Next we
measured the effects of xenon or sevoflurane as labor analgesics
on neuronal activity using c-Fos expression in the spinal cord. One
hour after delivery of the first pup, the number of c-Fos positive
neurons in the spinal cord layer I–II was significantly higher in the
control group (2265) as compared to those in the naı¨ve group
(260.2), xenon group (562) and sevoflurane group (660.3,
p,0.01, n = 4, Figure 2), indicating that xenon or sevoflurane at
the administered concentration can prevent the nociception
induced by labor in rats.
Fetal asphyxia
Asphyxia causes apoptosis, which is ameliorated by
xenon and sevoflurane: To assess the protective effects of
xenon or sevoflurane exposure prior to injury on the brain, the
neuronal cell injury or cell death were measured by caspase-3 and
cresyl violent staining on PND 3 and 7 respectively. An example of
a high magnification area from the hippocampus (CA1) is
illustrated in Figure 3A. The pups from the dams preconditioned
by sevoflurane or xenon had significantly less caspase-3 positive
cells (3166, 2863 respectively) after asphyxia when compared to
the pups exposed to hypoxia alone (4766, p,0.05, n = 6) at PND
3. The number of caspase-3 positive cells in the naı¨ve controls
(vaginal delivery) was 2264, which is significantly lower than pups
exposed to hypoxia alone (p,0.05, n = 6), but overall not different
from sevoflurane or xenon (Figure 3B). To assess morphological
changes in the brain and to corroborate the caspase-3 findings, we
used sections stained with cresyl violet to assess neuronal loss.
Minor changes were observed in cortical areas, however the
hippocampus showed most robust and significant differences, with
clear neuronal loss in the control group as compared to any other
treatment on PND 7 (p,0.01, Figure 4).
Figure 1. Pain stretching behavior during labor. The time course (A) and counting (B) of stretches, either inward turning of the hind paw or
straining of the abdomen, which represent uterus contraction-related pain 90 min prior to birth delivery. Dams from sevoflurane or xenon groups
had a significant decrease of stretches compared to control group. Data are expressed as mean 6 SEM (n = 4); **p,0.01. Bar = 100 mm.
doi:10.1371/journal.pone.0037020.g001
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Postnatal memory deficit is improved following treat-
ment with xenon and sevoflurane: In order to assess
neuropathological amelioration afforded by xenon or sevofluane
exposure prior to injury leading to cognitive improvement, we
used WM to assess learning and memory functions at the juvenile
stage on PND 50. Latency to locate the hidden platform was
significantly decreased in animals exposed to sevoflurane or xenon
as compared to pups exposed to hypoxia alone (Figure 5A). We
used the Area under Curve (AUC) to denote the cumulative
average time of the four trials based on the five testing days. There
was a significant difference comparing pups exposed to hypoxia
alone with naı¨ve group (p,0.05, Figure 5A and B). Pups exposed
to hypoxia alone spent a shorter time in the platform area in the
probe trial as compared to naı¨ve, sevoflurane or xenon treated
groups (p,0.05, Figure 5C). There was no significant difference in
swimming speed among groups (Figure 5D).
Discussion
In this study we have demonstrated that (i) peri-labor
administration of the anesthetic agents sevoflurane or xenon
provide effective alleviation of nociception induced by labor in
rats, and (ii) preconditioning with either agent for four hours prior
to fetal asphyxia offered neuroprotection and ameliorated
cognitive dysfunction.
Figure 2. c-Fos expression in the spinal. Rats were divided into naı¨ve group (virgin female rats exposed in 30% oxygen balanced by 70%
nitrogen), control group (parturient rats exposed in 30% oxygen balanced by 70% nitrogen), sevoflurane group (parturient rats exposed in 0.35%
sevoflurane in 30% oxygen balanced by nitrogen), or xenon group (parturient rats exposed in 35% xenon in 30% oxygen balanced by nitrogen).
Photomicrographs show c-Fos expression in the dorsal horn at the lumbosacral level of the spinal cord (A). B shows the quantification of c-Fos
positive cells. Data are expressed as mean 6 SEM (n = 4). **p,0.01. Bar = 100 mm. The inserted box indicates the area being subjected to high
magnification image.
doi:10.1371/journal.pone.0037020.g002
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The visceral component of labor pain, from the uterus to the
lower thoracic and upper lumbar spinal cord segments, relays on
c-fiber afferent signaling [11]. C-Fos is a prototypical neuronal
marker for nociceptive signaling in spinal cord [12]. Because of the
cross-innervations of nerves in the spinal cord, c-Fos expression as
induced by parturition is detectable through segments T12-S2 of
the spinal cord, but in particular between L5-S1. Immunohisto-
chemistry study demonstrated that c-Fos expression is detectable
in the spinal cord 30 min after peripheral nociceptive stimulation,
with levels peaking between 60 and 90 min [12]. Concurrent to
these molecular changes, stereotypic behavior associated with the
visceral nociception in response to uterine stimulation can be
assessed in rats [7,13]. In our current study, we measured
nociceptive behavior assessing stretches and c-Fos expression in
the spinal cord 1 h after delivery of the first pup. The number of
uterine contraction-related stretches significantly increased with
time until all pups were delivered (Figure 1B). This is consistent
with the clinical observations that labor pain increases with time
and peaks during the second stage of labor and during delivery of
the baby. Here we demonstrated that the administration of xenon
or sevoflurane to the dam remarkably reduced dam’s stretches
before delivery (Figure 1A). This was associated with significantly
lower c-Fos expression in the dorsal horn of the spinal cord as
compared to untreated control (Figure 2). The changes in behavior
and c-Fos expression following xenon or sevoflurane administra-
tion are similar to the effects of epidural analgesia with morphine
[7], suggesting that both 35% xenon and 0.35% sevoflurane exert
antinociceptive effect during labor in rats. A clinical trial showed
the best concentration of sevoflurane for labor analgesia was 0.8%
and, though sedation was noticed, it was safe and associated with
higher maternal satisfaction than nitrous oxide [14]. In our pilot
studies we saw severe sedation of the dams and delayed labor with
sevoflurane concentrations .0.5%. This may be due to the
different administration method: in the clinical trial patients used
sevoflurane intermittently according to their needs, whereas in our
animal model, sevoflurane is given continuously. However we
cannot exclude that the behavioral changes we observed were not
due to increased sedation rather than antinociception which has
been well documented previously in this model with morphine
administrated intrathecally [13], hence the importance of the c-
Fos data to confirm antinociceptive effects.
Figure 3. Caspase 3 expression in the hippocampus. Pups from
control, sevoflurane or xenon groups experienced intrauterine hypoxia,
when the dams were exposed in different gases during labor. Pups from
naı¨ve group were from vaginal delivery from surrogate mother.
Photomicrographs show caspase 3 expression in the hippocampus on
PND3, CA1, (A, 206). B shows the quantification of caspase 3 positive
cells. Results are expressed as mean 6 SEM (n = 5). *p,0.05.
Bar = 100 mm. The inserted box indicates the area being subjected to
high magnification image.
doi:10.1371/journal.pone.0037020.g003
Figure 4. Morphological changes in the hippocampus. Photo-
micrographs show cresyl violet staining in CA1 region of hippocampus
(A, 406) on PND 7. Neuronal loss, cellular disorganization and shrinkage
were attenuated in sevoflurane or xenon groups compared to control
group. There is a significant difference in the number of healthy cells in
control group, compared to all other groups (B). Results are mean 6
SEM (n = 6). * p,0.05, **p,0.01.
doi:10.1371/journal.pone.0037020.g004
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The analgesic effects of xenon and sevoflurane have been
proven pre-clinically and clinically [14,15,16,17,18,19]. Xenon
appears to exert its antinociceptive effect, at least partially, by
directly acting on the spinal cord [20], conversely nitrous oxide has
limited effects on the spinal cord [21]. It has been suggested that
the analgesic properties of sevoflurane may be mediated by
GABAergic signaling [22], however the specific molecular
mechanisms of the analgesic effects of inhalational aesthetics
remain unclear.
Our previous studies demonstrated that xenon and sevoflurane
protected the neonatal neuronal system from brain injury [6],
suggesting that xenon and sevoflurane may be ideal alternatives to
nitrous oxide for labor analgesia, with the added benefit of
protecting the neonates from the unanticipated hypoxic-ischemic
injury. To investigate whether xenon or sevoflurane could serve
this dual function during labor, we used our established model of
perinatal asphyxia [8], in which the hypoxic insult occurs in utero
during labor and can lead to global brain injury. This model
closely simulates the course of perinatal ischemia and hypoxia and
is consequently more suitable for testing potential therapeutic
approaches to protect the vulnerable fetal brain from the
consequences of ischemia and hypoxia. This study shows that
the administration of 35% xenon or 0.35% sevoflurane to
pregnant dams reduced neuronal apoptosis and cell death in the
hippocampus of the pups (Figure 3 & 4). This was associated with
attenuation in long-term cognitive dysfunction following intra-
uterine ischemia/hypoxia injury (Figure 5).
The neuroprotective properties of xenon and sevoflurane has
been evaluated in both in vivo and in vitro studies
[6,9,23,24,25,26,27,28,29], but the underlying mechanisms have
not been clearly identified. Xenon is a competitive N-methyl-D-
aspartate (NMDA) receptor antagonist at the glycine site [30,31],
which may contribute to xenon-induced neuroprotective effects
[32]. In vitro work showed that the adenosine triphosphate-sensitive
potassium (KATP) channel can also be activated by xenon [33],
however sevoflurane preconditioning possibly relies on mitochon-
drial KATP [34]. In our recent study, we demonstrated that xenon
alone or in combination with sevoflurane protects against ischemic
injury and the effect is mediated by PI3K and pCREB signaling
pathway [6,25,35]. In addition, sevoflurane is thought to provide
neuroprotection via anti-inflammatory effects which is a possible
mechanism of protection against perinatal brain injury [36,37].
Xenon does not appear to be teratogenic nor has been
associated with neurodegeneration and has been used in an
apparently safe manner in neonates for many years for neuroim-
aging. However there are some reports about sevoflurane which
are less reassuring although it is much less toxic than isoflurane at
the equipotent concentration [38]. One study suggested after
exposure to 3% sevoflurane, the mice developed learning deficit
and abnormal social behavior [39]. Another acute gas exposure
model showed 6 h sevoflurane exposure (2.1% or 3%) may induce
neurotoxicity in 7-day-old mice especially in Alzheimer disease
transgenic mice [40]. It is important to note that in these studies
sevoflurane was used at concentrations of 2.1% or 3.0%. However,
in the labor analgesia setting, sevoflurane is used at much lower
concentration [14] hence the neonatal toxicity may be less of a
concern. Due to technical difficult of the nature work, the blood
gases were not monitored during labor analgesia period although
the respiratory rate was within the normal physiological range.
Therefore, blood gas changes induced by anesthetic exposure, if
any, would be minimal and would not distort our conclusions, i.e.
fetal brain protection which was assessed a few hours after
anesthetic exposure.
Conclusion
Our data indicate that both xenon and sevoflurane adminis-
tered for 4 h before asphyxia at concentrations that can provide
antinociception during labor and also protect against intrauterine
fetal hypoxic-ischemic brain injury in an experimental rat model
of hypoxia/ischemia. These data suggest that in the clinical
Figure 5. Neurocognitive behavior at PND 50. A shows the
average latencies, the time required for each animal to reach the hidden
platform, of the four trials for the initial 5 days. B shows the area under
curve (AUC) derived from A. C shows the percentage of the time the
rats spent in the platform area in the probe trial on the 6th testing day.
Control group have significant neurocognitive impairment when
compared to naı¨ve group. There is no difference between sevoflurane,
xenon groups and naı¨ve group. D shows there is no difference in the
average velocity in each group. Data are expressed as mean 6 SEM
(n = 5–6) and compared by one-way analysis of variance and Student-
Newman-Keuls method. * p,0.05, **p,0.01.
doi:10.1371/journal.pone.0037020.g005
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setting, xenon or sevoflurane for labor analgesia may not only
provide effective analgesia but also prevent brain injury in the
compromised fetus that extends into neuroprotection of the
newborn following birth.
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